Advertisement

Delay of Progression of Renal Failure

  • Mackenzie Walser

Abstract

It has become traditional to view chronic renal failure as a process that progresses inexorably toward the point at which no significant amount of renal function remains. Occasional patients seem not to progress or even to improve, but these are infrequent exceptions to the general rule. Because of the generality of this observation, it also has become traditional to accept this inexorable progression as an inevitable phenomenon. Generally it is assumed that unless the etiologic agent can be removed, for example, by discontinuing analgesic intake in analgesic nephropathy or by controlling blood pressure in hypertensive nephropathy, continuing damage to the remaining nephrons by the disease process will occur.

Keywords

Chronic Renal Failure Essential Amino Acid Serum Phosphate Plasma Creatinine Analgesic Nephropathy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Walser M: Keto-analogues of essential amino acids, in Clinical Nutrition Update: Amino Acids. Chicago, American Medical Association, 1977, p 183.Google Scholar
  2. 2.
    Walser M, Sapir DG, Mitch WE, et al: Evidence for an anabolic action of essential amino acid analogues in uremia and starvation. Zeit Ernahrung Suppl 119: S5, 1977.Google Scholar
  3. 3.
    Mitch WE, Buffington GA, Lemann J, et al: A simple method of estimating progression of chronic renal failure. Lancet 2: 1326, 1976.PubMedCrossRefGoogle Scholar
  4. 4.
    Rutherford WE, Blondin J, Miller JP, et al: Chronic progressive renal disease: Rate of change of serum creatinine concentration. Kidney Int 11: 62, 1977.PubMedCrossRefGoogle Scholar
  5. 5.
    Leumann EP: Progression of renal insufficiency in pediatric patients: Estimation from serum creatinine. Heiv Paediatr Acta 33: 25, 1978.Google Scholar
  6. 6.
    Arbus GS, Bacheyie GS: Method for predicting when children with progressive renal disease may reach high serum creatinine levels. Pediatrics 67: 871, 1981.PubMedGoogle Scholar
  7. 7.
    Reimold EW: Use of serum creatinine to predict terminal renal failure in chronic progressive renal disease in children. Kidney Int 16: 936, 1979.Google Scholar
  8. 8.
    Gretz N. Huber W, Gretz T, et al: Zur Anwendung mathematischer Modelle für die Verlaufsbeschreibung der chronischen Niereninsuffizienz. Nieren-and Hochdruckkrankheitin 9: 117, 1980.Google Scholar
  9. 9.
    Jones RH, Hayakawa H, Mackay JD, et al: Progression of diabetic nephropathy. Lancet 1: 1105, 1979.PubMedCrossRefGoogle Scholar
  10. 10.
    Talwalkar YB, Mandel S: Monitoring the progression of chronic renal failure. Lancet 1: 366, 1977.PubMedCrossRefGoogle Scholar
  11. 11.
    Barsotti G, Guiducci A, Ciardella F, et al: Effects on renal function of a low-nitrogen diet supplemented with essential amino acids and ketoanalogues and of hemodialysis and free protein supply in patients with chronic renal failure. Nephron 27: 113, 1981.PubMedCrossRefGoogle Scholar
  12. 12.
    Mitch WE, Walser M: A proposed mechanism for reduced creatinine excretion in severe chronic renal failure. Nephron 21: 248, 1978.PubMedCrossRefGoogle Scholar
  13. 13.
    Doolan PD, Alpen EL, Theil GB: A clinical appraisal of the plasma concentration and endogenous clearance of creatinine. Am J Med 32: 65, 1962.PubMedCrossRefGoogle Scholar
  14. 14.
    Enger E, Biegen EM: The relationship between endogenous creatinine clearance and serum creatinine in renal failure. Scand J Clin Lab Invest 16: 273, 1964.PubMedCrossRefGoogle Scholar
  15. 15.
    Goldman R: Creatinine excretion in renal failure. Proc Soc Exp Biol Med 85: 446, 1954.PubMedGoogle Scholar
  16. 16.
    Mitch WE, Collier, VU, Walser M: Creatinine metabolism in chronic renal failure. Clin Sci 58: 327, 1980.PubMedGoogle Scholar
  17. 17.
    Walser M: Conservative management of the uremic patient, in Brenner BM, Rector, FC (eds): The Kidney, volume II. Philadelphia, WB Saunders, 1981, p 2383.Google Scholar
  18. 18.
    Collier VU, Mitch WE, Walser M: Effects of spontaneous or induced lowering of plasma CA X P product on progression of chronic renal failure (CRF). Clin Res 26: 564A, 1978.Google Scholar
  19. 19.
    Rutherford E, King S, Perry B, et al: Use of a new phosphate binder in chronic renal insufficiency. Kidney Int 17: 528, 1980.PubMedCrossRefGoogle Scholar
  20. 20.
    Walser M, Mitch WE, Collier VU: Essential amino acids and their nitrogen-free analogues in the treatment of chronic renal failure, in Schreiner G (ed): Controversies in Nephrology. Washington, DC, Georgetown University Division of Nephrology, 1979.Google Scholar
  21. 21.
    Walser M, Mitch WE, Collier VU: The effect of nutritional therapy on the course of chronic renal failure. Clin Nephrol 11: 66, 1979.PubMedGoogle Scholar
  22. 22.
    Walser M: Calcium carbonate-induced effects on serum Ca X P product and serum creatinine in renal failure: A retrospective study, in SG Massry, Ritz E, John H (eds): Phosphate and Minerals in Health and Disease. New York, Plenum Press, 1980, p 281.Google Scholar
  23. 23.
    Makoff D, Gordon A, Franklin SS, et al: Chronic calcium carbonate therapy in uremia. Arch Intern Med 123: 15, 1969.PubMedCrossRefGoogle Scholar
  24. 24.
    Berlyne GM: Calcium carbonate and uremic acidosis. Isr J Med Sci 7: 1235, 1971.PubMedGoogle Scholar
  25. 25.
    Johnson WJ, Goldsmith RS, Jowsey J, et al: The influence of maintaining normal serum phosphate and calcium on renal osteodystrophy, in Norman AW (ed): Vitamin D and Problems Related to Uremic Bone Disease. Bern, Walter de Gruyter, 1975, p. 561.Google Scholar
  26. 26.
    Maschio G, Oldrizzi L, Tessitore N, et al: Effects of dietary protein and phosphorus restriction on the progression of early renal failure. Kidney Int (in press).Google Scholar

Copyright information

© Plenum Publishing Corporation 1982

Authors and Affiliations

  • Mackenzie Walser
    • 1
  1. 1.Department of Pharmacology and Experimental Therapeutics and Department of MedicineJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations